Neurocrine Biosciences (NASDAQ:NBIX) Given New $215.00 Price Target at Cantor Fitzgerald

Neurocrine Biosciences (NASDAQ:NBIX) had its price objective lifted by Cantor Fitzgerald from $210.00 to $215.00 in a research report sent to investors on Friday morning,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the stock.

Other equities analysts also recently issued research reports about the stock. The Goldman Sachs Group initiated coverage on shares of Neurocrine Biosciences in a report on Tuesday, June 2nd. They issued a “buy” rating and a $213.00 price objective on the stock. BMO Capital Markets upped their target price on shares of Neurocrine Biosciences from $144.00 to $170.00 and gave the company a “market perform” rating in a report on Monday, July 13th. Wall Street Zen upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 25th. Citigroup lifted their price target on shares of Neurocrine Biosciences from $242.00 to $246.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Neurocrine Biosciences from $177.00 to $185.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $199.64.

Neurocrine Biosciences Stock Down 10.1%

Neurocrine Biosciences stock opened at $166.80 on Friday. Neurocrine Biosciences has a 52-week low of $122.14 and a 52-week high of $186.12. The company has a market cap of $16.77 billion, a P/E ratio of 24.46, a P/E/G ratio of 0.78 and a beta of 0.39. The business has a 50-day simple moving average of $167.81 and a two-hundred day simple moving average of $146.40.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Jude Onyia sold 11,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $160.25, for a total transaction of $1,762,750.00. Following the sale, the insider owned 25,846 shares in the company, valued at approximately $4,141,821.50. This trade represents a 29.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephen A. Sherwin sold 25,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $165.32, for a total transaction of $4,133,000.00. Following the transaction, the director directly owned 15,860 shares in the company, valued at $2,621,975.20. This represents a 61.18% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 395,422 shares of company stock worth $62,448,693 in the last quarter. 4.60% of the stock is currently owned by insiders.

Institutional Trading of Neurocrine Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of NBIX. Generali Investments Management Co LLC raised its position in shares of Neurocrine Biosciences by 19.8% during the 2nd quarter. Generali Investments Management Co LLC now owns 10,644 shares of the company’s stock valued at $1,794,000 after purchasing an additional 1,762 shares during the period. Handelsbanken Fonder AB lifted its stake in shares of Neurocrine Biosciences by 9.6% during the 2nd quarter. Handelsbanken Fonder AB now owns 205,871 shares of the company’s stock valued at $34,696,000 after buying an additional 18,004 shares in the last quarter. Fulton Bank N.A. boosted its holdings in Neurocrine Biosciences by 5.2% in the 2nd quarter. Fulton Bank N.A. now owns 4,895 shares of the company’s stock worth $825,000 after buying an additional 243 shares during the period. Valeo Financial Advisors LLC bought a new position in Neurocrine Biosciences in the 2nd quarter worth $283,000. Finally, Trust Point Inc. purchased a new stake in Neurocrine Biosciences in the 2nd quarter worth $245,000. 92.59% of the stock is owned by hedge funds and other institutional investors.

Neurocrine Biosciences News Summary

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Strong Q2 performance: Second-quarter revenue rose 39% year over year to $959 million, exceeding the approximately $891 million analyst estimate. Adjusted earnings were $2.85 per share versus the $2.26 consensus, while net income increased to $144.4 million. Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
• Positive Sentiment: Product and pipeline growth: INGREZZA sales increased 15% to $716 million, while CRENESSITY generated $184 million and newly acquired VYKAT XR contributed $54 million. Neurocrine also raised its 2026 INGREZZA sales guidance to $2.825 billion-$2.875 billion, supporting the company’s commercial outlook and Soleno Therapeutics acquisition. NBIX Q2 Earnings Call Highlights
• Positive Sentiment: Analyst support strengthened: TD Cowen, Guggenheim, Stifel, Cantor Fitzgerald, Piper Sandler, Needham, RBC and Morgan Stanley all raised their price targets, with targets ranging from $196 to $222. William Blair also reiterated a Buy rating, citing strong execution and substantial pipeline potential. Analyst Price Target Updates
• Neutral Sentiment: Investor expectations remain elevated: Although NBIX beat quarterly estimates, the market appears to have wanted a larger revenue upside surprise or more aggressive full-year guidance. The reaction suggests investors may be reassessing how much near-term upside is already reflected in the shares.
• Negative Sentiment: Insider selling adds a cautionary signal: Director Leslie Norwalk sold 1,250 shares for about $228,000 under a pre-arranged Rule 10b5-1 plan. Broader data also show numerous insider sales and no open-market purchases over the past six months, though such transactions may be planned and do not necessarily indicate deteriorating fundamentals. SEC Insider Trading Filing

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.